HB-0036 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback